DGCR11

Across TCGA pan-cancer cohorts, DGCR11 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of DGCR11’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where DGCR11 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types DGCR11 is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

LIHC, HNSC, and UCEC are the cancer types where DGCR11 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DGCR11 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	All	+0.928	<.001	9	view →
HNSC	Male	All	+0.627	<.001	8	view →
UCEC	All	All	+0.574	<.001	6	view →
CHOL	Male	All	+1.670	<.001	5	view →
STAD	Male	II,III,IV	+0.509	.001	4	view →
KICH	All	All	−0.415	.004	4	view →
BRCA	Female	All	+0.257	<.001	4	view →
KIRC	All	All	+0.217	.004	4	view →
PAAD	Female	All	+0.174	.049	2	view →
LUAD	All	II,III,IV	+0.299	.034	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

DGCR11–LIHC

Open the LIHC breakdown →